BioSpace News Archive

Business

Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results

Conference Call to be held Thursday, August 8, 2019 at 5:00 pm EDT

August 8, 2019
·
10 min read
Bio NC

IQVIA Announces Repurchase of Common Stock

IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility.

August 8, 2019
·
1 min read
Business

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019

Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 Program

August 8, 2019
·
15 min read
Business

Taro Provides Results for Quarter Ended June 30, 2019

Taro Pharmaceutical Industries today provided unaudited financial results for the quarter ended June 30, 2019.

August 8, 2019
·
8 min read
Business

Intrexon Reports Second Quarter and First Half 2019 Financial Results

Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million

August 8, 2019
·
17 min read
Deals

/C O R R E C T I O N -- Achieve Life Sciences, Inc./

Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update

August 8, 2019
·
7 min read
Business

APA President Calls For Comprehensive Public Health Approach To Gun Violence

Crisis should be handled in the same manner motor vehicle deaths were successfully addressed, she says

August 8, 2019
·
2 min read
Business

Medicure Reports Financial Results for Quarter Ended June 30, 2019

Recorded net revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $6.2 million during the quarter ended June 30, 2019 compared to $7.2 million for the quarter ended June 30, 2018 and $4.8 million for the quarter ended March 31, 2019

August 8, 2019
·
12 min read
Deals

Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes - Aug. 8, 2019

Clovis Oncology, Inc. announced the pricing of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

August 8, 2019
·
5 min read
Policy

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on Behalf of Corindus Shareholders and Encourages Corindus Investors to Contact the Firm

Pursuant to the proposed transaction, announced on August 8, 2019 and valued at $1.1 billion, Corindus shareholders will receive $4.28 in cash for each share of Corindus common stock owned.

August 8, 2019
·
1 min read